Key result
SGLT2i therapy is linked to ~74% fewer arrhythmic episodes in HFrEF with cardiac devices.
Why the study?
The antiarrhythmic effect of SGLT2 inhibitors on atrial and ventricular arrhythmias in HFrEF patients with cardiac implantable electronic devices was unclear.
Does SGLT2i therapy reduce atrial and ventricular arrhythmias in HFrEF patients with ICD/CRT-D?
Observational (n=198)
No
Does SGLT2i therapy reduce atrial and ventricular arrhythmias in HFrEF patients with ICD/CRT-D?
SGLT2 inhibitors significantly reduce the burden of both atrial and ventricular arrhythmias in patients with HFrEF and implantable defibrillators.
Answers are grounded in this paper and cite their sources.
May suggest antiarrhythmic benefit in HFrEF device patients; hypothesis-generating and requires RCT confirmation.
BACKGROUND: Sodium glucose cotransporter 2 inhibitors (SGLT2i) represent one of the four pillars of heart failure (HF) pharmacological therapy. OBJECTIVE: The study aims to clarify SGLT2i antiarrhythmic effect on patients with HF with reduced ejection fraction (HFrEF) in terms of atrial and ventricular arrhythmias (AAs and VAs) reduction. METHODS: HFrEF carriers of implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D) followed by remote monitoring of Policlinico Umberto I of Rome for 1 year before and after SGLT2i therapy initiation were enrolled in the study. We compared the incidence of AAs and VAs as recorded at remote monitoring during 1 year preceding SGLT2i therapy initiation and after 1 year of SGLT2i therapy. RESULTS: Among 198 enrolled patients, 135 patients had arrhythmic events before SGLT2i therapy prescription. There were 1353 arrhythmic events recorded in the year before SGLT2i therapy prescription, and 354 events were detected in the year after SGLT2i initiation, with a 73.8% reduction in events number after therapy initiation. After SGLT2i therapy initiation, the median number of total arrhythmic episodes significantly decreased from a median of 7 [3;12] to 1 [0;4] (P value < 0.001), AAs significantly decreased from a median of 4 [3;7] to 1 [0;3] episodes (P value < 0.001) and VAs were reduced from a median of 5.5 [3;10] to 0 [0;2] (P value < 0.001). When considering arrhythmia subtypes, larger reductions were recorded for atrial fibrillation (AF) episodes, reduced from 4 [3;8] to 0 [0;3], non-sustained ventricular tachycardia (NSVT) that decreased from 4 [2;8.75] to 0 [0;2] (P value < 0.001) and for sustained ventricular tachycardia (SVT) that were reduced from 3 [2;4] to 0 [0;1] (P value < 0.001). CONCLUSIONS: In HFrEF carriers of ICD/CRT-D, the use of SGLT2i resulted in significant reduction of AA and VA events.
No takes yet. Share an insight, caveat, or question.
Mariani et al. (2025) conducted an observational in Heart failure with reduced ejection fraction (HFrEF) with ICD or CRT-D (n=198). Sodium glucose cotransporter 2 inhibitors (SGLT2i) vs. 1 year preceding SGLT2i therapy initiation was evaluated on Total arrhythmic episodes (73.8% reduction, p=< 0.001). SGLT2i therapy in patients with HFrEF and an ICD/CRT-D reduced the median number of total arrhythmic episodes from 7 to 1 over 1 year.
Synapse has enriched 10 related papers. Consider them for comparative context: